Serine/threonine protein kinase AKT, an important target of the phosphoinositide‐3‐kinase/AKT signaling pathway, is abnormally activated in various types of tumor, including those in head and neck cancer (Amornphimoltham et al., 2004) (including OTSCC) (Massarelli et al., 2005). This evidence concerns the gene MARK2 and neoplasm.